FSH treatment of male idiopathic infertility improves pregnancy rate: a meta-analysis

D Santi¹ ², A R M Granata² and M Simoni¹ ²

¹Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
²Unit of Endocrinology, Azienda USL of Modena, NOCSAE, Via P. Giardini 1355, 41126 Modena, Italy

Abstract

Introduction: The aim of this study is to comprehensively evaluate whether FSH administration to the male partner of infertile couples improves pregnancy rate, spontaneously and/or after assisted reproductive techniques (ART).

Methods: Meta-analysis of controlled clinical trials in which FSH was administered for male idiopathic infertility, compared with placebo or no treatment. Randomization was not considered as an inclusion criterion.

Results: We found 15 controlled clinical studies (614 men treated with FSH and 661 treated with placebo or untreated). Concerning the type of FSH, eight studies used recombinant FSH, whereas seven studies used purified FSH. Nine studies evaluated spontaneous pregnancy rate, resulting in an overall odds ratio (OR) of about 4.5 (CI: 2.17–9.33). Eight studies evaluated pregnancy rate after ART, showing a significant OR of 1.60 (CI: 1.08–2.37). Sub-dividing studies according to the FSH preparations (purified/recombinant), pregnancy rate improvement remained significant for each preparation. Eleven studies considered sperm quality after FSH treatment, finding a significant improvement of sperm concentration (2.66 x 10⁶/ml, CI: 0.47–4.84), but not of concentration of sperm with progressive motility (1.22 x 10⁵/ml, CI: −0.07 to 2.52). Three trials evaluated testicular volume, showing a non-significant increase in men treated (1.35 ml, CI: −0.44 to 3.14).

Conclusion: The results of controlled clinical trials available in the literature indicate an improvement of pregnancy rate after FSH administration to the male partner of infertile couples, both spontaneously and after ART. However, the heterogeneity of studies, the high risk of bias and the lack of precise criteria to guide FSH administration limit the strength of these results. Future studies should be designed to identify the markers of FSH response which are helpful in the decision-making process. Meanwhile, the use of FSH in the treatment of male infertility should be cautious.
Introduction

Rationale

Infertility is conventionally defined as a clinical condition affecting a couple failing to conceive after a period of 12 months of regular intercourse without contraception (1). Male infertility plays a significant role in ~50% of couples experiencing a delay in conceiving (2). A careful and complete diagnostic workup allows for recognition of the most important male infertility causes (3). However, the underlying pathophysiological mechanism remains idiopathic in about 30% of cases, which fall in the category of ‘male idiopathic infertility’ (2). The medical treatment of infertility may be specific or non-specific. Specific treatments are used for certain etiologies, such as hypogonadotropic hypogonadism, male accessory gland infection, retrograde ejaculation, and positive antisperm antibody (4). Non-specific treatments are hormonal and non-hormonal therapies, proposed for the treatment of idiopathic infertile men (5, 6).

Assisted reproductive techniques (ART) based on IVF were introduced to clinical practice in 1978 (7), and progressively extended its indication from female, tubal infertility to unexplained couple infertility. Currently, intracytoplasmatic-sperm injection (ICSI) is the most frequently used ART (8). The outcome of ICSI seems to be influenced by sperm structure and quality (9). Thus, it seems reasonable that an improvement in sperm quality could effect ICSI outcomes.

The empirical administration of follicle stimulating hormone (FSH) to infertile men has been reported in the literature since 1991 to variably improve fertilization and pregnancy rate (10, 11). This therapy is popular in some countries, although doubts remain on its efficacy in the treatment of infertile men, particularly in the ART setting. A significant increase in pregnancy rate after IVF and male treatment with FSH was shown in some studies (12, 13), while other trials did not find the same improvement (14). Recently, the Cochrane Collaboration estimated the overall effect of FSH treatment of the man in couples attending ART enrolled in randomised, controlled, clinical trials (15). This meta-analysis demonstrates that FSH treatment significantly improves spontaneous pregnancy rate, whereas no improvement of pregnancy rate is observed after ART, probably because only one randomized clinical trial (RCT) was included (15). These results were obtained by evaluating only randomized, controlled, clinical trials, using fixed and strict inclusion criteria (15). The authors excluded quasi-RCTs, cross-over (if data before the cross-over was not available), and excluded all trials in which randomization was not carried out (15). Therefore, only six RCTs, the most recent thereof published in 2006 (16), were included in the meta-analysis. The absence of further RCTs in this field of medicine in the last decade reflects the difficulty of conducting a randomized approach in infertile couples, in which the woman is nearing the end of her reproductive age, as a swift successful pregnancy is required. Finally, Attia et al. (15) evaluated pregnancy rate as an outcome of FSH treatment without assessing separately purified and recombinant FSH formulations.

Objectives

The aim of this study was to comprehensively evaluate whether FSH administration to the male partner of infertile couples improves pregnancy rate, spontaneously and/or after ART, by performing a meta-analysis of all controlled clinical trials.

Materials and methods

We performed a meta-analysis according to the Cochrane Collaboration and PRISMA statement (17, 18).

Data sources and searches

We conducted a comprehensive literature search for English-language articles in MEDLINE (PubMed), EMBASE, the Cochrane Library, SCOPUS and UpToDate. Search key words were: FSH, FSH treatment, FSH therapy, follicle-stimulating hormone, gonadotropin, infertility, male infertility, IVF, intracytoplasmatic sperm injection, IVF, ICSI and the Boolean functions AND and OR.

Study selection and inclusion criteria

Types of studies ➤ Controlled clinical trials in which FSH was administered for male idiopathic infertility, compared with placebo or no treatment. Randomization was not considered as inclusion criterion, thus both randomized and non-RCTs were reviewed.

Type of participants ➤ Men with idiopathic infertility or subfertility. All semen abnormalities (from mild oligozoospermia to severe oligo-astheno-teratospermia)
were considered eligible, independently of the changes over time of the normality ranges for semen analysis by the World Health Organization (WHO). Azoospermic men were not considered eligible. Controls were not treated or placebo-treated idiopathic infertile or sub-fertile men. No inclusion criteria were applied for the female partner of the infertile couple.

**Type of interventions** Chronic treatment with any type of FSH, compared with placebo or no treatment.

**Data collection process and quality**

One author (D S) extracted the abstracts from all studies found through the literature search. All abstracts were evaluated for inclusion criteria and data were extracted from each study considered eligible, with regard to study design, year of publication, number of included/excluded subjects, number of dropped-out patients and the use of intention to treat/per protocol analysis. Furthermore, D S extracted study subjects’ demographics and underlying diseases, with particular attention to the time elapsed from the first attempt to conceive.

All controlled study designs were considered eligible. We included studies assessing efficacy of FSH administration to the male partner of infertile couples in order to improve fertilization. The quality of trials was assessed using the parameters proposed by Jadad *et al.* (19) and Table 1 summarizes the features of the selected studies.

Studies considered in the meta-analysis used different endpoints. Some studies evaluated spontaneous pregnancy rate, occurring after unprotected intercourse, whereas other studies evaluated fertilization and pregnancy rate occurring after ART. We performed an overall meta-analysis which considered all studies that evaluated pregnancy rate. Subsequently, we separately evaluated pregnancy rate, either spontaneously or after ART.

Semen analysis, a surrogate fertility marker, was routinely performed using light microscopy. In all studies, semen samples were collected by masturbation, generally after 3–4 days of sexual abstinence, and liquefied at 37 °C.

The other investigators (M S, A R G) performed quality control checks on the extracted data (Fig. 1). The investigators, using the Cochrane risk-of-bias algorithm, independently assessed the risk of bias for all trials (20). The following quality criteria and methodological details were evaluated for each trial included in the meta-analysis: i) method of randomization, even if the randomization was not an inclusion criterion, ii) concealment of allocation, iii) presence or absence of blinding to treatment allocation, iv) duration and type of treatment and follow-up phases, v) number of participants recruited, analyzed or lost to follow-up, vi) timing of trial, vii) whether an intention to treat analysis was done, viii) whether a power calculation was done, ix) source of funding, and x) criteria for including participants and assessing outcomes.

**Summary measures**

The primary outcome was pregnancy rate, evaluated as an odds ratio (OR) between treated and control men. Secondary outcomes were semen analysis parameters. Sperm quality (i.e. sperm concentration and progressive motility) and testicular volume were considered as mean differences. Sperm motility was assessed as the number of progressive motile sperm, calculated considering only the percentage of sperm with progressive motility out of the total sperm number.

**Data synthesis and analysis**

The meta-analysis was conducted using the Review Manager (RevMan) 5.3 Software (Version 5.3.1 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Data were combined using the fixed effect model for the primary endpoint, considering the reliability in the evaluation of pregnancy. However, the random effect model was used for secondary endpoints, providing a more conservative estimate of the overall effect, considering the intrinsic inaccuracy of parameters such as sperm quality. Weighted mean differences and 95% CIs were estimated for each endpoint. Heterogeneity among the results of different studies was examined by inspecting both the scatter in the data points and the overlap in their CIs, and by performing $\chi^2$ tests and $I^2$ statistics. The $I^2$ statistics answer the question: what proportion of the observed variance reflects real differences in effect size? It is a measure of inconsistency across the findings of the studies, not a measure of the real variation across the underlying true effects. Values of $P < 0.05$ were considered statistically significant.

**Risk of bias across studies**

The authors (D S, A R G, M S) independently evaluated risk of bias. Publication bias is a bias towards reporting significant results, despite the fact that studies with significant results do not appear to be superior to studies with a null result with respect to result quality (21, 22). A simple analysis of funnel plots provides a useful test for
Table 1  Characteristics of studies included in the meta-analysis.

| References | Number of treated patients | Number of control patients | Mean age (years) | Baseline sperm concentration of treated patients (million/ml) | Baseline sperm morphology of treated patients (%) | Baseline FSH of treated patient (IU/L) | Baseline sperm concentration of controls (million/ml) | Baseline sperm morphology of controls (%) | Baseline FSH of controls (IU/L) | Drugs | Cumulative FSH dose (IU) | Duration (weeks) | Parameters evaluated |
|------------|---------------------------|---------------------------|------------------|---------------------------------------------------------------|-----------------------------------------------|---------------------------------------|---------------------------------------------------|------------------------------------------|----------------------------------|-------|------------------------|----------------------|---------------------|
| (12)       | 39                        | 39                        | –                | –                                                             | –                                             | –                                    | –                                                | –                                        | –                                 | Purified FSH (Metrodin) | 6300                | 12                   | PR                  |
| (14)       | 24                        | 20                        | 8.81             | –                                                             | 12.42                                         | –                                    | –                                                | –                                        | –                                 | Purified FSH (Fertinorm) | 12 600              | 12                   | PR, FR, semen analysis |
| (35)       | 31                        | 101                       | 31.5             | –                                                             | –                                             | –                                    | –                                                | –                                        | –                                 | Purified FSH (Metrodin) | 2100                | 4                    | PR, semen analysis     |
| (36)       | 20                        | 20                        | 31.7             | 6.4 ± 2.4                                                     | –                                             | 6.4 ± 2.6                             | –                                                | 6.4 ± 2.6                                 | –                                 | Purified FSH (Metrodin) | –                   | 2 IVF cycles          | PR, FR               |
| (37)       | 23                        | 10                        | 35.3             | 1.3 ± 2.2                                                     | 9.7 ± 6.05                                    | 2.5 ± 2.2                             | 30.0 ± 12.9                                   | 10.5 ± 6.8                                 | –                                 | Recombinant FSH (Gonal F) | 5400                | 12                   | PR, FR, semen analysis |
| (38)       | 65                        | 63                        | 32.6             | 7.8 ± 2.7                                                     | 20.6 ± 5.0                                    | 8.1 ± 2.2                             | 21.8 ± 4.7                                    | 6.1 ± 1.6                                 | –                                 | Recombinant FSH (Gonal F) | 6750                | 12                   | semen analysis, sDF   |
| (41)*      | 77                        | 20                        | 32               | 4.7 ± 5.1                                                     | –                                             | 9.0 ± 8.9                             | 61.2 ± 38.8                                   | –                                        | 2.6 ± 1.6                           | Purified FSH (Metrodin) | 3375                | 12                   | semen analysis        |
| (40)*      | 30                        | 55                        | 32.6             | 4.8 ± 2.6                                                     | 4.1 ± 2.2                                    | 63.2 ± 39.2                           | –                                                | 2.8 ± 1.5                                 | –                                 | Recombinant FSH (Gonal F) | 2250                | 12                   | semen analysis        |
| (39)       | 65                        | 90                        | 34.2             | 6.4 ± 3.5                                                     | 25.3 ± 6.2                                    | 6.8 ± 3.2                             | 26.2 ± 6.8                                    | 4.8 ± 1.4                                 | –                                 | Recombinant FSH (Gonal F) | 4500                | 12                   | semen analysis        |
| (42)       | 57                        | 62                        | 34.2             | 1.8 ± 0.7                                                     | 20.7 ± 8.4                                    | 15.1 ± 5.8                             | 18.1 ± 9.9                                    | 14.7 ± 6.6                                 | –                                 | Recombinant FSH (Gonal F) | 6750                | 12                   | semen analysis        |
| (13)       | 34                        | 33                        | 32.8             | 8.7 ± 1.5                                                     | 33.4 ± 3.0                                    | 5.0 ± 0.4                             | 8.7 ± 1.6                                    | 29.6 ± 3.0                                 | 5.6 ± 0.6                           | Recombinant FSH (Gonal F) | 12 600               | 12                   | semen analysis, TV    |
| (43)       | 19                        | 20                        | –                | –                                                             | –                                             | –                                    | –                                                | –                                        | –                                 | hMG                | –                    | 13                   | PR                  |
| (44)*      | 58                        | 78                        | –                | 69.5 ± 40.7                                                  | 27.5 ± 11.8                                  | 72.3 ± 43.2                           | 30.3 ± 12.3                                   | –                                        | –                                 | Purified FSH (Fertinorm) | –                   | unclear              |
| (16)       | 15                        | 15                        | –                | 7.6 ± 3.6                                                     | 9.4 ± 6.1                                    | 4.1 ± 1.6                             | 8.7 ± 5.5                                    | 4.3 ± 1.8                                 | –                                 | Recombinant FSH (Gonal F) | 18 000               | 16                   | semen analysis        |
| (45)       | 70                        | 35                        | –                | 4.0 ± 4.2                                                     | 20.8 ± 15.4                                   | 5.0 ± 1.8                             | 3.8 ± 0.4                                    | 20.1 ± 16.3                               | 4.9 ± 2.0                           | Recombinant FSH (Gonal F) | 5400                | 12                   | semen analysis        |

hMG, human menopausal gonadotropin, FR, fertilization rate, FSH, follicle-stimulating hormone, PR, pregnancy rate, sDF, sperm-DNA fragmentation, TV, testicular volume.

*Studies in which untreated normozoospermic infertile men of infertile couples were enrolled in the control group.
the likely presence of bias in meta-analyses, but as the capacity to detect bias will be limited when meta-analyses are based on a limited number of small trials, the results from such analyses should be treated with considerable caution (22). Funnel and Egger’s plots were performed using RevMan Software.

Additional analysis

Comparison between variables was performed with the Mann–Whitney U test. Meta-regression analysis was conducted by comparing sperm parameters to pregnancy rate. Number needed to treat (NNT) was calculated as the statistical inverse ratio of the absolute OR reduction. All additional analyses were performed using ‘Statistical Package for the Social Sciences’ Software for Macintosh (version 20.0; SPSS, Inc.).

Results

Study selection

Figure 1 shows the literature searching process, conducted from September 2014 to January 2015. From 568 studies initially found according to the research strategy, we identified 30 potentially relevant studies, based on the information given in the abstract. All trials were thoroughly appraised for eligibility in the meta-analysis and methodological quality. Fifteen studies were excluded from the final analysis since they did not fulfill the inclusion criteria (9, 10, 11, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34). Four studies were excluded because they were neither controlled nor cross-over studies (10, 11, 33, 34). Three studies were excluded because, although they aimed at evaluating the effect of gonadotropins in infertile couples, the study design did not provide the enrollment and the treatment criteria for the male partner (23, 25, 27). Four studies were excluded because they evaluated pregnancy rate in hypogonadotropic hypogonadic men (24, 30, 31, 32). Another trial was excluded because it evaluated the effect on sperm retrieval after testicular sperm extraction in azoospermic men after treatment with clomiphene citrate (26). Furthermore, another work was excluded because it was only a letter and not an original article (28). Finally, two studies were excluded because they were not clinical trials but reviews of sperm characteristics related to fertility (9, 29). Fifteen studies met the inclusion criteria (12, 13, 14, 16, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45) (Figure 1).

Study characteristics

All trials included were controlled against placebo or no treatment and enrolled the male partners of infertile couples attending ART Centers. By definition, the term ‘infertility’ was used after at least 1 year of unsuccessful intercourse (1). However, the duration of infertility considered in each study was different. Some trials considered infertile couples failing to conceive after 1 year, others after 2 years of unprotected intercourse. Furthermore, the definition of infertility in each trial was different. Some studies enrolled men with severe oligo-asthenoteratozoospermia, whereas others enrolled men with mild to moderate semen abnormalities, i.e. asthenozoospermia or teratozoospermia. The definition of these semen abnormalities was different, reflecting the WHO criteria, which changed during the time frame of the studies included.

Concerning the type of FSH, eight studies included in the meta-analysis used recombinant FSH (13, 16, 37, 38, 39, 40, 42, 45), whereas seven studies used purified FSH (12, 14, 36, 41, 43, 44, 45). Since the efficacy of recombinant and purified FSH was demonstrated to be similar (46) the type of FSH was not considered a source of bias.
Pregnancy rate, when evaluated, was considered spontaneous or after ART.

The different inclusion and exclusion criteria used in the studies included represent the most important source of heterogeneity in the estimation of the overall effect. This is a typical selection bias in studies involving infertile patients, considering several factors could influence couple fertility, from either the male or from the female side. The selected trials gave details about 1275 infertile men, 614 treated with FSH and 661 untreated (545) or placebo-treated (116).

**Risk of bias in included studies**

Figure 2 summarizes the risk of bias.

**Allocation (selection bias)**

Nine studies were RCTs and precisely specified the methodology of randomization (12, 13, 14, 38, 39, 40, 42, 43, 45). The other six studies included were non-randomized, controlled, clinical trials, with potential selection bias due to the lack of randomization.

**Blinding (performance bias and detection bias)**

The nine RCTs were double-blinded (12, 13, 14, 38, 39, 40, 42, 43, 45).

**Incomplete outcome data (attrition bias)**

The drop-out rate of patients enrolled in the trials included was similar. Only five trials correctly reported the drop-out rate, and the evaluation of data after drop-out (13, 38, 39, 42, 44). The remaining studies included in the meta-analysis neither reported the drop-out rate nor gave information about the evaluation of patient drop-out.

**Selective reporting (reporting bias)**

The primary endpoints described in the aims were reported in the results section of each study. Several studies included secondary endpoints, which, however, were not always completely reported in the results and discussion sections.

**Other potential sources of bias**

None of the trials reported a calculation of the sample size in the study design.

**Synthesis of results**

Considering the lack of a unique, validated pharmacodynamics marker of FSH administration in men, the major endpoint of FSH treatment efficacy in male infertility is pregnancy rate. Among the 15 studies included, 12 trials considered pregnancy rate after FSH administration to the male partner, for a total of 482 infertile men treated, compared to 393 control men (12, 13, 14, 16, 35, 36, 37, 39, 42, 43, 44, 45) (Fig. 3A). First of all, baseline FSH levels were generally within or slightly above the normal range. There were no significant differences in basal FSH serum levels between treated and not-treated men (6.89 ± 3.48 vs 6.27 ± 3.69 mIU/ml, P = 0.052). On the contrary, sperm concentration at baseline was significantly higher in the group of men not treated with FSH, compared to those treated (22.56 ± 27.91 vs 11.40 ± 19.44 × 10⁶/ml, P < 0.001), confirming a lack of randomization.

A significant improvement in pregnancy rate was found in treated men. The overall OR was 2.09 with CI 1.46–3.01 (P < 0.001) (Fig. 3A). χ² was 10.09 and I² statistics 0% (Fig. 3A). The I² statistics showed a low degree of inconsistency of this result. Significant improvement in pregnancy rate remained dividing the analysis in randomized (OR 1.55, CI 1.0–2.4, P = 0.05), and not-RCTs (OR 3.96, CI 1.87–8.37, P < 0.001).

Assessing pregnancy rate, we further performed two subgroup meta-analyses, keeping spontaneous and ART pregnancies separate. The first subgroup analysis included...
nine studies in which spontaneous pregnancy rate was reported or evaluated as the main outcome (12, 13, 16, 37, 39, 42, 43, 44, 45). A total of 384 men were treated, compared to 308 controls during the study protocol. The pregnancy rate improved significantly after FSH treatment, with an OR of about 4.5, with a CI 2.17–9.33 (P<0.001) (Fig. 3B). χ² was 2.29 and I² statistics 0% (Fig. 3B). This increased pregnancy rate was confirmed both in five RCTs (OR 5.15, CI 2.01–13.15, P<0.001), and in four not-RCTs (OR 3.70, CI 1.17–11.73, P=0.003), suggesting that the lack of randomization did not impair the result. The second subgroup meta-analysis considered eight studies evaluating pregnancy rate after ART, independently of the ART methods applied (12, 13, 14, 36, 37, 39, 42, 44). A total of 322 men were treated, compared to 275 controls. Pregnancy rate significantly improved after FSH treatment, with an OR of about 1.60 and CI 1.08–2.37 (P=0.02) (Fig. 3C). χ² was 206.08 and I² statistics 95% (Fig. 3A). Furthermore, we analyzed six studies which considered progressive sperm motility (13, 37, 38, 41, 44, 45). A total of 332 men were treated, compared to 297 controls. The meta-analysis showed a non-significant improvement of progressive sperm motility after FSH and the mean improvement was 1.22×10⁶/ml (CI –0.07 to 2.52) (P=0.06) (Fig. 4B). χ² was 1851.9 and I² statistics 100% (Fig. 4B).

Three trials reported testicular volume (13, 37, 45). A total of 127 FSH-treated men and 76 controls were compared. The results showed an increase of testicular volume in FSH-treated men, but this increase was not statistically significant (P=0.14). The mean increase was 1.35 ml, with CI 0.34 to 3.14. χ² was 2.68 and I² statistics 25%. Considering the two studies in which testicular volume was evaluated by ultrasonography, this parameter did not change after FSH treatment (P=0.44) (13, 45). In particular, Selice et al. (45) gave neither any information about the mathematical formula used for testicular volume calculation by ultrasonography, nor found any significant variation in this parameter after treatment. In contrast, Kamischke et al. (13) reported the method applied for testicular volume calculation and found a significant increase after FSH treatment. These discrepancies do not demonstrate a clear FSH effect on testicular size.

### Additional analysis

Meta-regression analysis showed no significant correlation between pregnancy rate and sperm concentration, progressive motility and testicular volume (P=0.502, P=0.175 and P=0.854, respectively). Sperm concentration correlations were not found with progressive motility, nor with testicular volume (P=0.925 and P=0.203, respectively).

The visual evaluation of funnel plots did not reveal publication bias in the studies considered.

### Discussion

Here we confirm the beneficial effect of FSH administration to the male partner of couples with idiopathic infertility in terms of pregnancy rate improvement, either spontaneously or after ART. This finding extends that recently obtained by the Cochrane Collaboration which was limited to spontaneous pregnancy (15). Some features
### A

| Reference | Odds ratio M-H, Fixed, 95% CI |
|-----------|-------------------------------|
|           |                              |
| (12)      |                              |
| (14)      |                              |
| (35)      |                              |
| (36)      |                              |
| (37)      |                              |
| (39)      |                              |
| (42)      |                              |
| (43)      |                              |
| (44)      |                              |
| (45)      |                              |

### B

| Reference | Odds ratio M-H, Fixed, 95% CI |
|-----------|-------------------------------|
|           |                              |
| (12)      |                              |
| (37)      |                              |
| (39)      |                              |
| (42)      |                              |
| (43)      |                              |
| (44)      |                              |
| (45)      |                              |

### C

| Reference | Odds ratio M-H, Fixed, 95% CI |
|-----------|-------------------------------|
|           |                              |
| (12)      |                              |
| (14)      |                              |
| (36)      |                              |
| (37)      |                              |
| (39)      |                              |
| (42)      |                              |
| (43)      |                              |
| (44)      |                              |
| (45)      |                              |

### D

| Reference | Odds ratio M-H, Fixed, 95% CI |
|-----------|-------------------------------|
|           |                              |
| (12)      |                              |
| (37)      |                              |
| (39)      |                              |
| (42)      |                              |
| (43)      |                              |
| (44)      |                              |
| (45)      |                              |

### E

| Reference | Odds ratio M-H, Fixed, 95% CI |
|-----------|-------------------------------|
|           |                              |
| (12)      |                              |
| (39)      |                              |
| (42)      |                              |
| (43)      |                              |
| (44)      |                              |
| (45)      |                              |

---

### Raw Text

**Heterogeneity:**

Test for overall effect: $Z=3.69$ ($P=0.0001$)

Heterogeneity: $I^2=0\%$

Test for overall effect: $Z=4.04$ ($P<0.0001$)

---

### Table

| FSH treatment | Control group |
|---------------|---------------|
| Reference     | Events Total  | Events Total  | Total Events Total Events | Weight (%) | M-H, Fixed, 95% CI |
| (12)          | 18 39 7 39   | 21 39 7 39    | 39 39 7 39                | 9.0        | 3.92 (1.40, 11.00) |
| (14)          | 8 24 4 20   | 8 24 4 20     | 16 24 8 20               | 6.9        | 2.00 (0.50, 8.00)  |
| (35)          | 2 31 0 31   | 2 31 0 31     | 4 31 0 31                | 11.1       | 5.34 (0.25, 110.89) |
| (36)          | 3 40 0 20   | 3 40 0 20     | 6 40 0 20                | 2.4        | 3.83 (0.19, 77.78) |
| (37)          | 7 23 0 10   | 7 23 0 10     | 14 23 7 10               | 1.1        | 9.55 (0.49, 182.21) |
| (39)          | 16 65 12 63 | 16 65 12 63   | 32 65 24 63             | 21.9       | 1.39 (0.60, 3.23)  |
| (42)          | 4 57 0 30   | 4 57 0 30     | 8 57 0 30               | 1.4        | 5.13 (0.27, 96.56) |
| (43)          | 8 31 10 30  | 8 31 10 30   | 16 31 20 30           | 17.9       | 0.70 (0.23, 2.10)  |
| (44)          | 2 19 0 20   | 2 19 0 20     | 4 19 0 20              | 1.0        | 5.86 (0.26, 130.36) |
| (45)          | 36 68 31 80 | 36 68 31 80   | 72 68 62 80            | 31.9       | 1.78 (0.92, 3.42)  |
| (16)          | 4 15 0 15   | 4 15 0 15     | 8 15 0 15              | 0.9        | 12.13 (0.59, 248.49) |
| (45)          | 10 70 2 35  | 10 70 2 35   | 20 70 4 35             | 5.4        | 2.75 (0.57, 13.30) |

Total events: 118 66

Heterogeneity: $I^2=10.09$, df=11 ($P=0.52$); $I^2=0\%$

Test for overall effect: $Z=3.99$ ($P<0.0001$)

---

### Table

| Reference | Odds ratio M-H, Fixed, 95% CI |
|-----------|-------------------------------|
|           |                              |
| (12)      |                              |
| (37)      |                              |
| (39)      |                              |
| (42)      |                              |
| (43)      |                              |
| (44)      |                              |
| (45)      |                              |

### Table

| Reference | Odds ratio M-H, Fixed, 95% CI |
|-----------|-------------------------------|
|           |                              |
| (12)      |                              |
| (37)      |                              |
| (39)      |                              |
| (42)      |                              |
| (43)      |                              |
| (44)      |                              |
| (45)      |                              |

### Table

| Reference | Odds ratio M-H, Fixed, 95% CI |
|-----------|-------------------------------|
|           |                              |
| (12)      |                              |
| (37)      |                              |
| (39)      |                              |
| (42)      |                              |
| (43)      |                              |
| (44)      |                              |
| (45)      |                              |

### Table

| Reference | Odds ratio M-H, Fixed, 95% CI |
|-----------|-------------------------------|
|           |                              |
| (12)      |                              |
| (37)      |                              |
| (39)      |                              |
| (42)      |                              |
| (43)      |                              |
| (44)      |                              |
| (45)      |                              |

### Table

| Reference | Odds ratio M-H, Fixed, 95% CI |
|-----------|-------------------------------|
|           |                              |
| (12)      |                              |
| (37)      |                              |
| (39)      |                              |
| (42)      |                              |
| (43)      |                              |
| (44)      |                              |
| (45)      |                              |

### Table

| Reference | Odds ratio M-H, Fixed, 95% CI |
|-----------|-------------------------------|
|           |                              |
| (12)      |                              |
| (37)      |                              |
| (39)      |                              |
| (42)      |                              |
| (43)      |                              |
| (44)      |                              |
| (45)      |                              |

---

### Raw Text

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
of our meta-analysis are, however, different. In particular, we used broader inclusion criteria, due to the difficulty in performing RCTs in the field of infertility, demonstrated by the lack of randomized studies on FSH for male infertility published in the last decade. Furthermore, we analysed the treatment effect on pregnancy rate while distinguishing between the FSH formulations used. Finally, we estimated the overall effect of FSH treatment on other outcomes, i.e. sperm concentration, progressive sperm motility and testicular volume.

Considering pregnancy rate, this meta-analysis confirms the beneficial effect of FSH administration to the male partner of infertile couples, demonstrating an improvement in spontaneous pregnancies (15). Furthermore, we demonstrate, for the first time, that FSH administration to the male partner is able to increase pregnancy rate after ART, independent of the ART methodology. This improvement in pregnancy rate remains even when recombinant or purified FSH are considered separately, suggesting that the two FSH preparations have a similar efficacy (Fig. 3D and E). Similarly, an improved pregnancy rate was confirmed when randomized and not-RCTs were considered separately, suggesting that lack of randomization does not impair the quality of the results. However, these results should be viewed in light of the broad inclusion criteria and high risk of bias. With this in mind, pregnancy rate increases in men treated with FSH, even if the OR is low, and additional analysis suggests that 10–18 men should be treated to achieve one additional pregnancy. This might sound marginal, but considering the costs of ART and the woman’s burden for the treatment of male infertility versus the cost of FSH treatment (irrespective of recombinant or extractive), this option should be given a trial.

The best tool for the evaluation of male fertility in clinical practice remains semen analysis. However, its interpretation is difficult, because of the inherent variability of the parameters and lack of clear-cut threshold values (47, 48). Several studies demonstrated a beneficial effect of FSH on the quality of spermatozoa (9, 14, 49), and an algorithm was proposed to improve the interpretation of semen analysis (49). Our results demonstrate an improvement of sperm concentration after treatment with FSH (Fig. 4A and B). However, a high degree of heterogeneity was evident ($I^2$ of 95%) and progressive sperm motility did not significantly improve after treatment. We interpret this difference as a sign of methodological inconsistency in semen analysis itself (48), as well as a heterogeneity of the inclusion criteria of the patients.

Even if conventional semen analysis does not provide accurate information about the spermatozoa’s ability to fertilize the egg, this meta-analysis demonstrates that FSH administration to infertile men improves sperm concentration and increases pregnancy rate. However, no correlation between sperm parameters and pregnancy rate was found. Evaluating the baseline characteristics of patients enrolled, we found that basal FSH serum levels were not different between study and control groups. Men not treated with FSH have higher baseline sperm concentration compared to treated men, reflecting the fact that some of the included studies were not randomized. Considering these limits, FSH administration increases sperm concentration irrespective of the basal FSH serum levels and absolute sperm number. This result suggests that basal FSH serum levels and sperm concentration do not represent a useful marker in the decision making process of whether to treat or not. Sperm morphology is a weak parameter, considering the spontaneous variability over the years, as evident from the different thresholds proposed by the various editions of the WHO manual to define normal morphology. Considering that studies included in the meta-analysis were conducted using different WHO manuals, it is not possible to compare this parameter with a statistical approach. Finally, other parameters, such as sperm DNA fragmentation, could be useful in the future to direct the decision-making process of whether or not to treat infertile men (38).

In animal models, FSH administration stimulates spermatogenesis and increases Sertoli cell secretions (50). In monkeys, the proliferation of spermatogenetic cells, together with Sertoli cells secretions, results in a testicular volume increase after 6 weeks of FSH administration (50). Some studies in men reported a testicular enlargement caused by a FSH-secreting pituitary adenoma (51) followed by a significant volume reduction after normalization of FSH levels (51). Since Sertoli cell number is constant after

Figure 3
Pregnancy rate. (A) Forest plot of 15 studies evaluating pregnancy rate after FSH administration. (B) Forest plot of nine studies evaluating spontaneous pregnancy rate after FSH administration. (C) Forest plot of eight studies evaluating pregnancy rate during ART, after FSH administration. The results are divided according to the use of recombinant (D) or purified (E) FSH. The diamond indicates the overall summary estimate for the analysis (width of the diamond represents the 95% CI); boxes indicate the weight of individual studies in the pooled analysis.

DOI: 10.1530/EC-15-0050
© 2015 Society for Endocrinology
Published by Bioscientifica Ltd

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
In conclusion, FSH administration to infertile men improves pregnancy rate, even if the OR is low and 10–18 men need to be treated to achieve one additional pregnancy. However, treated men were very heterogeneous and the usefulness of FSH treatment probably depends on the precise definition of the baseline condition and selection criteria of the infertile man. The studies included in the meta-analysis are limited by: i) empirical unstandardized FSH treatment use; ii) heterogeneity of the infertile men enrolled; iii) heterogeneity of the studies included, possibly related to an unknown female factor, as suggested by the relative high risk of bias (Fig. 2); iv) different lengths of treatment and follow-up phases used. Our results show the impossibility of defining a basal FSH serum level or basal sperm concentration which could distinguish responders from non-responders. Other predictors of response to FSH treatment should be identified, considering the relevance in clinical practice of distinguishing those men who will respond to FSH treatment from those who will not. A pharmacogenetic approach was suggested (54) and

In our meta-analysis the lack of testicular volume increase after FSH treatment remains when considering the two studies in which ultrasonography was performed. Thus, the FSH-induced improvement of sperm concentration without a significant increase in testicular size remains intriguing.

In conclusion, FSH administration to infertile men improves pregnancy rate, even if the OR is low and 10–18 men need to be treated to achieve one additional pregnancy. However, treated men were very heterogeneous and the usefulness of FSH treatment probably depends on the precise definition of the baseline condition and selection criteria of the infertile man. The studies included in the meta-analysis are limited by: i) empirical unstandardized FSH treatment use; ii) heterogeneity of the infertile men enrolled; iii) heterogeneity of the studies included, possibly related to an unknown female factor, as suggested by the relative high risk of bias (Fig. 2); iv) different lengths of treatment and follow-up phases used. Our results show the impossibility of defining a basal FSH serum level or basal sperm concentration which could distinguish responders from non-responders. Other predictors of response to FSH treatment should be identified, considering the relevance in clinical practice of distinguishing those men who will respond to FSH treatment from those who will not. A pharmacogenetic approach was suggested (54) and
could help the decision-making process while new fertility-related markers need to be identified to quantify the efficacy of FSH treatment. New markers, such as sperm DNA fragmentation (38), could help clinicians in the decision-making process, both as a prediction marker and pharmacodynamics parameter of FSH treatment. However, this parameter requires further evaluation.

Conclusions

FSH administration to the male is sometimes used for the empirical treatment of infertile couples. However, its efficacy remains unclear. The results of the clinical trials available in the literature, considered together in this meta-analysis, indicate an improvement of pregnancy rate after FSH administration to the male partner of infertile couples, both spontaneously or after ART. Furthermore, this meta-analysis suggests an improvement of sperm concentration after FSH administration, without a testicular size increase. However, a standardized FSH treatment protocol of male idiopathic infertility does not exist. Since a specific predictor of response to FSH administration is not available, the use of FSH in men with infertility should be judicious. Future clinical trials should be designed to define who will and who will not respond to FSH treatment.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector. D. Santi is recipient of a PhD fellowship of the Doctorate School of Clinical and Experimental Medicine of the University of Modena and Reggio Emilia.

Author contribution statement

All three authors participated in the literature search, analysis, and discussion of the results of the meta-analysis, as well as writing the manuscript.

References

1 Isaksson R & Tiitinen A. Present concept of unexplained infertility. Gynecological Endocrinology 2004 18 278–290. (doi:10.1080/0951359042000199878)
2 de Kretser DM. Male infertility. Lancet 1997 349 787–790. (doi:10.1016/S0140-6736(96)08341-9)
3 Wang C & Swerdloff RS. Limitations of semen analysis as a test of male fertility and anticipated needs from newer tests. Fertility and Sterility 2014 102 1502–1507. (doi:10.1016/j.fertnstert.2014.10.021)
4 Leifke E & Nieschlag E. Male infertility treatment in the light of evidence-based medicine. Andrologia 1996 28 (Suppl 1) 23–30.
5 Jung JH & Seo JT. Empirical medical therapy in idiopathic male infertility: promise or panacea? Clinical and Experimental Reproductive Medicine 2014 41 108–114. (doi:10.5653/erm.2014.41.3.108)
6 Rittenberg V & El-Toukhy T. Medical treatment of male infertility. Human Fertility 2010 13 208–216. (doi:10.3109/14442723.2010.534835)
7 Edwards RG. Maturation in vitro of human ovarian oocytes. Lancet 1965 2 926–929. (doi:10.1016/0140-6736(65)92923-X)
8 Nyhøe Andersen A, Carlens E & Løft A. Trends in the use of intracytoplasmatic sperm injection marked variability between countries. Human Reproduction Update 2008 14 593–604. (doi:10.1093/humupd/dnm032)
9 Baccetti B, Strehler E, Capitani S, Colodrel G, De Santo M, Moretti E, Piomboni P, Wiedeman R & Sterzik K. The effect of follicle stimulating hormone therapy on human sperm structure (Noueulae seminologicae 11). Human Reproduction 1997 12 1955–1966. (doi:10.1093/humrep/12.9.1955)
10 Acosta AA, Khalifa E & Oehninger S. Pure human follicle stimulating hormone has a role in the treatment of severe male infertility by assisted reproduction: Norfolk’s total experience. Human Reproduction 1992 7 1067–1072.
11 Acosta AA, Oehninger S, Ertunc H & Philput C. Possible role of human follicle-stimulating hormone in the treatment of severe male-factor infertility by assisted reproduction: preliminary report. Fertility and Sterility 1991 55 1150–1156.
12 Ashkenazi J, Bar-Hava I, Farhi J, Levy T, Feldberg D, Orvieto R & Ben-Rafael Z. The role of purified follicle stimulating hormone therapy in the male partner before intracytoplasmic sperm injection. Fertility and Sterility 1999 72 670–673. (doi:10.1016/S0015-0282(99)00222-2)
13 Kamischke A, Behre HM, Bergmann M, Simoni M, Schaler T & Nieschlag E. Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial. Human Reproduction 1998 13 596–603. (doi:10.1093/humrep/13.3.596)
14 Baccetti B, Piomboni P, Bruni E, Capitani S, Gambera L, Moretti E, Sterzik K & Strehler E. Effect of follicle-stimulating hormone on sperm quality and pregnancy rate. Asian Journal of Andrology 2004 6 133–137.
15 Attia AM, Abou-Setta AM & Al-Inany HG. Gonadotrophins for idiopathic male-factor subfertility. Cochrane Database of Systematic Reviews 2013 8 CD005071. (doi:10.1002/14651858.CD005071.pub2)
16 Paradisi R, Busacchi P, Seracchioli R, Porcu E & Venturoli S. Effects of high doses of recombinant human follicle-stimulating hormone in the treatment of male factor infertility: results of a pilot study. Fertility and Sterility 2006 86 728–731. (doi:10.1016/j.fertnstert.2006.02.087)
17 Moher D, Altman DG, Liberati A & Tetzlaff J. PRISMA statement. Epidemiology 2011 22 128. (doi:10.1097/EDE.0b013e3181fe7825)
18 Moher D, Liberati A, Tetzlaff J & Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. International Journal of Surgery 2010 8 336–341. (doi:10.1016/j.ijsu.2010.02.007)
19 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ & McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996 17 1–12. (doi:10.1016/0197-2456(95)00134-4)
20 Chandler J, Clarke M & Higgins J. The Cochrane Collaboration. Cochrane Methods. Eds J Chandler, M Clarke & J Higgins. UK: John Wiley & Sons Ltd, 2012.
21 Easterbrook PJ, Berlin JA, Gopalan R & Matthews DR. Publication bias in clinical research. Lancet 1991 337 867–872. (doi:10.1016/0140-6736(91)90201-Y)
22 Egger M, Davey Smith G, Schneider M & Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997 315 629–634. (doi:10.1136/bmj.315.7109.629)
 Berker B, Kahraman K, Taskin S, Sukur YE, Sonmez M & Atabekoglu S. Recombinant FSH versus clomiphene citrate for ovarian stimulation in couples with unexplained infertility and male subfertility undergoing intrauterine insemination: a randomized trial. *Archives of Gynecology and Obstetrics* 2011 **284** 1561–1566. (doi:10.1007/s00404-011-1997-4)

 Dwyer AA, Sykiotis GP, Hayes FJ, Boepple PA, Lee H, Loughlin KR, Dym M, Siass PM, Crowley WW Jr & Pitteloud N. Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism. *Journal of Clinical Endocrinology and Metabolism* 2013 **98** E1790–E1795. (doi:10.1210/jc.2013-2518)

 Goldman MB, Thornton KL, Ryley D, Alper MM, Fung JL, Bouloux P, Warne DW & Loumaye E. Efficacy and safety of recombinant human follicle-stimulating hormone for induction of spermatogenesis and fertility in men with idiopathic oligoasthenoteratozoospermia. *Fertility and Sterility* 2000 **73** 23–30. (doi:10.1016/S0015-0282(99)00461-6)

 Caroppo E, Niederberger C, Viziello GM & D’Amato G. Recombinant human follicle-stimulating hormone as a pretreatment for idiopathic oligoasthenoteratozoospermia patients undergoing intracytoplasmic sperm injection. *Fertility and Sterility* 2003 **80** 1398–1403. (doi:10.1016/S0015-0282(03)02027-7)

 Colacurci N, Monti MG, Fornaro F, Izzo G, Lizzo P, Trotta C, Mele D & De Franciscis P. Recombinant human FSH reduces sperm DNA fragmentation in men with idiopathic oligoasthenoteratozoospermia. *Journal of Andrology* 2012 **33** 588–593. (doi:10.2146/jandrol.11.013326)

 Foresta C, Bettella A, Garolla A, Ambrosini G & Ferlin A. Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study. *Fertility and Sterility* 2005 **84** 654–661. (doi:10.1016/j.fertnstert.2005.03.055)

 Foresta C, Bettella A, Merico M, Garolla A, Ferlin A & Rossato M. Use of recombinant human follicle-stimulating hormone in the treatment of male factor infertility. *Fertility and Sterility* 2002 **77** 238–244. (doi:10.1016/S0015-0281(01)02966-1)

 Foresta C, Bettella A, Merico M, Garolla A, Plebani M, Ferlin A & Rossato M. FSH in the treatment of oligozooospermia. *Molecular and Cellular Endocrinology* 2000 **161** 89–97. (doi:10.1016/S0015-0282(03)02202-7)

 Snell R, Pratson B, Schifrin A, Elston R, Tew LW, Vaitukaitis JL & Rossato M. Gonadotropin administration after gonadotropin-releasing hormone agonist: a therapeutic option in severe testicular failure. *Fertility and Sterility* 2009 **92** 1326–1332. (doi:10.1016/j.fertnstert.2008.07.1766)

 Knuth UA, Honigl W, Bals-Pratsch M, Schleicher G & Nieschlag E. Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: a placebo-controlled, double blind trial. *Journal of Clinical Endocrinology and Metabolism* 1987 **65** 1081–1087. (doi:10.1210/jcem-65-6-1081)

 Matorras R, Perez C, Corcosnegostegu B, Pijoan JL, Ramon O, Delgado P & Rodriguez-Escudero FJ. Treatment of the male with follicle-stimulating hormone in intrauterine insemination with husband’s spermatozoa: a randomized study. *Human Reproduction* 1997 **12** 24–28. (doi:10.1093/humrep/12.1.24)

 Selice R, Garolla A, Pengo M, Caretta N, Ferlin A & Foresta C. The response to FSH treatment in oligozoospermic men depends on FSH receptor gene polymorphisms. *Human Reproduction Update* 2011 **17** 306–312. (doi:10.1093/humupd/dmr048)

 Baker K, Li J & Sabanegh E Jr. Analysis of semen parameters in male referrals: impact of reference limits, stratification by fertility categories, predictors of change, and comparison of normal semen parameters in subfertile couples. *Fertility and Sterility* 2015 **103** 59–65.s.e5. (doi:10.1016/j.fertnstert.2014.09.043)

 World Health Organization, Department of Reproductive Health and Research. WHO Laboratory Manual for the Examination and Processing of Human Semen, 5th edn. Ed TG Cooper. Geneva, Switzerland: WHO, 2010. (available at: http://whqlibdoc.wto.who.int/publications/2010/ 9789241547789_eng.pdf)

 Baccetti B, Bernieri G, Burrini AG, Colledelf G, Crisina N, Mirolli M, Moretti E & Piomboni P. Notulae seminologicae. 5. Mathematical evaluation of interdependent submicroscopic sperm alterations. *Journal of Andrology* 1995 **16** 356–371.

 van Alphen MM, van de Kunt HJ & de Rooij DG. Follicle-stimulating hormone stimulates spermatogenesis in the adult monkey. *Endocrinology* 1988 **123** 1449–1455. (doi:10.1210/endo-123-3-1449)
51 Heseltine D, White MC, Kendall-Taylor P, De Kretser DM & Kelly W. Testicular enlargement and elevated serum inhibin concentrations occur in patients with pituitary macroadenomas secreting follicle stimulating hormone. *Clinical Endocrinology* 1989 **31** 411–423. (doi:10.1111/j.1365-2265.1989.tb01265.x)

52 Lotti F & Maggi M. Ultrasound of the male genital tract in relation to male reproductive health. *Human Reproduction Update* 2015 **21** 56–83. (doi:10.1093/humupd/dmu042)

53 Behre HM, Nashan D & Nieschlag E. Objective measurement of testicular volume by ultrasonography: evaluation of the technique and comparison with orchidometer estimates. *International Journal of Andrology* 1989 **12** 395–403. (doi:10.1111/j.1365-2605.1989.tb01328.x)

54 Simoni M & Casarini L. Potential for pharmacogenetic use of FSH: a 2014-and-beyond view. *European Journal of Endocrinology* 2013 **170** R91–R107. (doi:10.1530/EJE-13-0624)